Harnessing UBR5 for targeted protein degradation of key transcriptional regulators.

Autor: Taherbhoy AM; Foghorn Therapeutics, 500 Technology Square Suite 700, Cambridge, MA 02139, USA., Daniels DL; Foghorn Therapeutics, 500 Technology Square Suite 700, Cambridge, MA 02139, USA. Electronic address: ddaniels@foghorntx.com.
Jazyk: angličtina
Zdroj: Trends in pharmacological sciences [Trends Pharmacol Sci] 2023 Nov; Vol. 44 (11), pp. 758-761. Date of Electronic Publication: 2023 Sep 26.
DOI: 10.1016/j.tips.2023.09.001
Abstrakt: Targeted protein degradation (TPD) has opened the door for drugging transcriptional regulators, yet the number of proteins targeted and E3 ligases utilized remain limited. Here, we highlight UBR5 and propose multiple strategies by which this E3 ligase could be modulated to drive degradation of key transcriptional targets implicated in disease.
Competing Interests: Declaration of interests A.M.T. and D.L.D. are employees and shareholders of Foghorn Therapeutics.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: